Lung Cancer
Volume 68, Issue 1 , Pages 44-50 , April 2010

Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue–serum pairs

We wish to dedicate this work to Lance W. Crocker (1944–2004), beloved father of KWJ, and Wei Zheng (1962–1991), courageous sister of LLC. Their losses to lung cancer and loving memories have made this work possible.

  • K.W. Jordan

      Affiliations

    • Department of Pathology, Massachusetts General Hospital, Harvard Medical School, United States
    • ,
  • C.B. Adkins

      Affiliations

    • Department of Pathology, Massachusetts General Hospital, Harvard Medical School, United States
    • ,
  • L. Su

      Affiliations

    • Department of Environmental Health, Harvard School of Public Health, Boston, MA, United States
    • ,
  • E.F. Halpern

      Affiliations

    • Department of Radiology, Massachusetts General Hospital, Harvard Medical School, United States
    • ,
  • E.J. Mark

      Affiliations

    • Department of Pathology, Massachusetts General Hospital, Harvard Medical School, United States
    • ,
  • D.C. Christiani

      Affiliations

    • Department of Medicine, Massachusetts General Hospital, Harvard Medical School, United States
    • Department of Environmental Health, Harvard School of Public Health, Boston, MA, United States
    • ,
  • L.L. Cheng

      Affiliations

    • Department of Pathology, Massachusetts General Hospital, Harvard Medical School, United States
    • Department of Radiology, Massachusetts General Hospital, Harvard Medical School, United States
    • Corresponding Author InformationCorresponding author at: Pathology Research, CNY-7, 149 13th Street, Charlestown, MA 02129, United States. Tel.: +1 617 724 6593; fax: +1 617 726 5684.

Received 3 December 2008 ,Revised 14 May 2009 ,Accepted 17 May 2009.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Report of the NCI Lung Cancer Progress Review Group, http://planning.cancer.gov/pdfprgreports/2001lung.pdf, 2001.
  3. Coleman RE. PET in lung cancer. J Nucl Med. 1999;40:814–820
  4. Higashi K, Matsunari I, Ueda Y, Ikeda R, Guo J, Oguchi M, et al. Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med. 2003;17:1–14
  5. Higashi K, Ueda Y, Ayabe K, Sakurai A, Seki H, Nambu Y, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun. 2000;21:707–714
  6. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med. 2000;41:85–92
  7. Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKenzie AF, et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596–1604
  8. Guo J, Higashi K, Yokota H, Nagao Y, Ueda Y, Kodama Y, et al. In vitro proton magnetic resonance spectroscopic lactate and choline measurements, 18F-FDG uptake, and prognosis in patients with lung adenocarcinoma. J Nucl Med. 2004;45:1334–1339
  9. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res. 2005;65:3030–3034
  10. Burns MA, He W, Wu CL, Cheng LL. Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol Cancer Res Treat. 2004;3:591–598
  11. Maillet S, Vion-Dury J, Confort-Gouny S, Nicoli F, Lutz NW, Viout P, et al. Experimental protocol for clinical analysis of cerebrospinal fluid by high resolution proton magnetic resonance spectroscopy. Brain Res Brain Res Protoc. 1998;3:123–134

PII: S0169-5002(09)00305-5

doi: 10.1016/j.lungcan.2009.05.012

Lung Cancer
Volume 68, Issue 1 , Pages 44-50 , April 2010

Article Tools

* Image Usage & Resolution